Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA
07:12 EDT 28 Jul 2012 | The Medical News
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Dr..
Original Article: Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA
More From BioPortfolio on "Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
